## **REMARKS/ARGUMENTS**

Reconsideration of this application is requested. Claims 1, 3-5, 7, 9, 10 and 12 remain active in the application subsequent to entry of this Amendment.

Applicants are pleased to see that the previous rejection directed to claims 8 and 9 has been withdrawn but new prior art has been cited.

Claim 1 has been amended in order to overcome the novelty rejection in view of newly cited Crandall et al.

In view of the Information Disclosure Statement filed on August 7, 2008, claim 1 has been further amended in order to patentably distinguish the claimed subject-matter in view of the documents cited in the IDS.

Claims 2 and 11 have been deleted. Claim 3 has been amended. Claim 5 is also amended to delete non-relevant compounds and minor adjustments made to claim 12.

Responsive to the anticipation rejection based upon the Crandall citation and directed to claims 1, 3, 4, 5 and 12, the claims have been suitably amended to exclude the compound disclosed in Crandall thus novelty is established and this rejection should be withdrawn.

Responsive to the lack of clarity rejection directed to claims 2, 3 and 11, claims 2 and 11 have been deleted. Claim 3 has been amended in order to clarify the meaning of Ar which is phenyl as defined in claim 1. This objection is no longer believed to be pertinent.

Claims 7, 9 and 11 are objected to as being dependent from a rejected base claim but otherwise allowable, according to counsel's understanding.

Reconsideration of this application and allowance of all pending claims is solicited. Should the examiner require further information or wish to discuss this application, please contact the undersigned.

GIANNESSI et al Appl. No. 10/501,135 December 23, 2008

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Arthur R. Crawford Reg. No. 25,327

ARC:eaw

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100